Table 5.
SBRT of abdominal lymph node oligometastases
| Patients (N) | Primary cancer | Dose (Gy) × fr | Median follow up (mos) | Outcomes | |
|---|---|---|---|---|---|
| Jereczek-Fossa et al. 2009 [53] |
14 |
Prostate |
33 (mean) × 3-5 |
Mean 18.6 |
- No in-field clinical progression |
| |
|
|
|
|
- Distant or regional LN progression at mean time of 12.7 mo |
| |
|
|
|
|
- All patients with relapse had high-risk disease |
| Bignardi et al. 2011 [54] |
19 |
CRC (5/19) |
45 × 6 |
12 |
Actuarial rate of freedom from local progression: 77.8 ± 13.9 at both 12 and 24 mos |
| |
|
|
|
|
Minimal acute and chronic toxicity |
| Choi et al. 2010 [55] |
30 |
Uterus and cervix |
EBRT: 27–45 (n = 4 pts) |
15 |
4-year LC rate: 67.4% |
| |
|
|
SBRT: 33–45 × 3 (n = 24 pts) |
|
4-year OS rate: 50.1% |
| |
|
|
|
|
(all 30 pts). |
| Kim et al. 2009 [56] |
7 |
Gastric (salvage aftersurgery) |
48 (median) × 3 |
26 |
Complete response: n = 5 |
| |
|
|
|
|
Partial response: n = 2 |
| Kim et al. 2009 [57] |
7 |
CRC |
Escalated dose 36–51 × 3 |
26 |
Median survival: 37 mos |
| |
|
|
|
|
1-year OS: 100% |
| |
|
|
|
|
3-year OS: 71.4% |
| |
|
|
|
|
G4: intestinal obstruction in 1/7 patients |
| Bae et al. 2012 [51] |
41 |
CRC |
48(45 – 60) × 3 |
28 |
-PFS, LC and OS rates |
| |
|
|
|
|
3-year rates : 40%, 64%, 60% |
| |
|
|
|
|
5-year rates : 40, 57%, 38% |
| -G3 perforation after pelvic LN SBRT;G4 obstruction of para-aortic LN SBRT |
EBRT: electron beam radiotherapy; CRC: colorectal cancer; LN: lymph node; LC: local control, OS: overall survival, G: grade.